Clinical trials: Covid19- Coronavirus- Sars-cov-2
Covid19, Vaccine Reaction
Evaluation of the Effect of Coronavac Vaccine (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 Vaccine) on Healthcare Workers' Menstrual Patterns
Coronavac, one of the vaccines developed within the scope of combating the COVID-19 pandemic that has surrounded the world for a year, started to be applied in the first healthcare workers in our country.
- Conditions
- Covid19, Vaccine Reaction, Coronavirus, Menstrual Problem
- Trial name
- NCT04854408
- Testing
- healthcare workers with the coronavac vaccine
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Kanuni Sultan Suleyman Training and Research Hospital
COVID-19
A Clinical Observational Study of SARS-CoV-2 Specific CD8 T-Cell Responses to COVID-19 Vaccines in Humans
Background: The immune response is how the body recognizes and defends itself against foreign and harmful substances. Researchers want to compare the immune responses between young and older healthy adults after they receive…
- Trial name
- NCT04852289
- Where
- 2 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute on Aging (NIA)
Coronavirus
Anti-SARS-CoV-2 Inactivated Convalescent Plasma in the Treatment of COVID-19
There is still no effective antiviral drugs and vaccines against SARS-CoV-2 yet now. This is an obsevational study, the investigators collected the clinical information and clinical outcomes of the COVID-19 patients using…
- Trial name
- NCT04292340
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai Public Health Clinical Center
Coronavirus Disease 2019, COVID-19
Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease
The Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY) study is a pragmatic prospective, open-label, randomised controlled trial.
- Trial name
- CLARITY (NCT04394117)
- Testing
- Angiotensin Receptor Blockers
- Where
- 22 sites in Australia, India
- Volunteers
- 787 people
- Sponsor
- The George Institute
Solid Organ Transplant Recipients
TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted Patients
Covid-19 has a very bad prognosis in solid organ transplant recipients with a 60 days-mortality exceeding 20%. For this reason, transplant patients were prioritized to receive Covid-19 vaccination since December 2020 in France.
- Trial name
- TIXCI-TRANS (NCT05234398)
- Testing
- Blood and saliva samplings
- Where
- 2 sites in France
- Sponsor
- Hospices Civils de Lyon
Covid19, Cardiac Arrest
COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment
During the Corona Virus Pandemic health care resources have become scare, and the pandemic has brought forth the need for risk stratification of patients suffering from COVID19 in order to allocate resources appropriately.
- Trial name
- CORDEAL (NCT04743232)
- Testing
- Decision tool for clinicians
- Where
- 7 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- Erasmus Medical Center
Covid19, Health Care Worker
Evaluation of the Prevalence of SARS-CoV-2 Infection in the Healthcare Workers (HCWs) in Four Hospital of the Alpine Region
The PACAAP study aims to report the seroprevalence of SARS-CoV-2 IgG antibodies among HCWs testing during the massive campaign screening set up in France by French ministry of Health and national authorities in four hospital of…
- Trial name
- PACAAP (NCT04845984)
- Where
- France
- Volunteers
- 3,500 people
- Sponsor
- Centre Hospitalier Annecy Genevois
Pulmonary Complications, Cardiovascular Complications
The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19
More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and…
- Conditions
- Pulmonary Complications, Cardiovascular Complications, Renal Complications, COVID-19
- Trial name
- POINT (NCT06608849)
- Testing
- Blood samples, Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
- Where
- 6 sites in Greece
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
Acute Respiratory Distress Syndrome Related to SARS-CoV-2
COronaVirus Induced Acute Respiratory Disease Syndrome During PREGnancy
Few data are available on the management of critically ill pregnant women with pneumonia related to SARS-CoV-2. In the absence of clear recommendations for the management of delivery, clinicians are faced with the risk of…
- Trial name
- COVADIS-PREG (NCT05193526)
- Testing
- No intervention
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
COVID-19 Virus Disease
Study to Evaluate the Safety and Concentrations of Monoclonal Antibody Against Virus That Causes COVID-19 Disease.
A Phase I dose-escalation study to test a new monoclonal antibody (called MAD0004J08) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19 disease.
- Trial name
- MAD0004J08 (NCT04932850)
- Testing
- MAD0004J08
- Where
- 2 sites in Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Toscana Life Sciences Sviluppo s.r.l.
Covid19, Cancer
Immune Response to the COVID-19 Vaccine
Explore the effects on immune response to include a potential third vaccine for the cancer cohort.
- Conditions
- Covid19, Cancer, Malignancy, Vaccine Response Impaired
- Trial name
- NCT04936997
- Testing
- SARS-COV2 Pfizer Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Arizona
SARS-CoV 2
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
The study will be a randomized, partially-blinded, prime-boost, staggered dose-escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three…
- Trial name
- NCT04450004
- Testing
- Intramuscular Vaccine
- Where
- 2 sites in Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicago
SARS-CoV-2
Seroprevalence of Coronavirus Disease 2019 (COVID-19) Antibodies in a Vulnerable Neighbourhood, Buenos Aries Argentina
Background The study aimed to establish the seroprevalence of SARS-COV-2 in an Argentinian slum three months after the first case was reported.
- Trial name
- NCT04472078
- Testing
- Serological Assay or IgG for SARS-CoV-2
- Where
- Argentina
- Volunteers
- 873 people
- Sponsor
- Hospital Italiano de Buenos Aires
COVID, Corona Virus Infection
Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers
The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have…
- Trial name
- NCT04424017
- Testing
- Specific anti-SARS-CoV-2 antibodies
- Where
- 2 sites in Egypt
- Volunteers
- 1,546 people
- Sponsor
- Egyptian Center for Research and Regenerative Medicine
COVID-19, Sars-CoV2
Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients
The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.
- Trial name
- CAPRI (NCT04421404)
- Testing
- COVID-19 Convalescent Plasma (CCP)
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Priscilla Hsue, MD
COVID-19
A Longitudinal Study of COVID-19 Sequelae and Immunity
Background: COVID-19 is a disease caused by the SARS-CoV-2 virus. It infects the respiratory tract. Some people who get COVID-19 have only mild symptoms.
- Trial name
- NCT04411147
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Intensive Care Unit, SARS-CoV2
Assessment of SARS-CoV-2 Effect on Post-traumatic Stress of Patients Hospitalized in Intensive Care Unit
Patients admitted to the intensive care unit develop psychiatric disorders, such as anxiety, depression or post-traumatic stress disorder, which can be prolonged.
- Trial name
- FAMILY-COVID (NCT04872049)
- Where
- France
- Volunteers
- 264 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Long COVID
Fatigability in Long COVID-19
The overall goal of this project is to advance the understanding of underlying mechanisms impacting performance fatigability and perceived fatigability in Veterans with post-COVID-19 fatigue and explore the safety and feasibility…
- Trial name
- NCT05699538
- Testing
- Minimal-Dose Home-Based Resistance Exercise
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- VA Office of Research and Development
SARS-CoV-2 Infection, Intensive Care Unit Patient
WHO Covid 19 - Neurological Abnormalities in SARS-CoV-2 ICU Patients
The SARS-CoV-2 epidemic is leading to a large number of patients in intensive care units due to severe hypoxemic pneumonia. After an acute phase that may require controlled mechanical ventilation and deep sedation, removal of…
- Conditions
- SARS-CoV-2 Infection, Intensive Care Unit Patient, Neurological Abnormality, Delirium
- Trial name
- NeuroCovid (NCT04643548)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Clermont-Ferrand
COVID-19, SARS-CoV-2 Infection
A Trial Evaluating the Safety and Immunogenicity of 3 COVID-19 SARS-CoV-2 RNA Vaccines in Healthy Adults
This is a Phase 1/2, randomized, observer-blind study in healthy adults. The study will evaluate the safety, reactogenicity, and immunogenicity of 3 SARS-CoV-2 self-amplifying RNA vaccine candidates against COVID-19 in adults…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Corona Virus Infection
- Trial name
- NCT05037097
- Testing
- ARCT-165, ARCT-154, ARCT-021
- Where
- 4 sites in United States, Singapore and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Arcturus Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.